A-HeFT
2004
African-American Heart Failure Trial
In 1,050 Black patients with NYHA III-IV HFrEF on standard therapy, fixed-dose isosorbide dinitrate plus hydralazine improved a composite of survival, HF hospitalisation and quality of life compared with placebo.
Result
Efficacy: Weighted composite score (all-cause death, first HF hospitalisation, change in quality of life)HR 0.57 · P = 0.01
Below 1 favours fixed-dose isosorbide dinitrate plus hydralazine, above 1 favours placebo.
- Absolute difference
- 4.0 points
- NNT
- 26
Absolute difference and NNT are derived from the event rates.
Also reported: Composite score significantly favoured active therapy; trial halted early for mortality benefit and fewer first HF hospitalisations (16.4% vs 22.4%).
- Subtopic
- hydralazine/nitrate
- Design
- Double-blind placebo-controlled RCT, stopped early for benefit
- Relevance
- Supporting: context rather than must-know.
- Cited in
- ESC 2021 HFAHA/ACC 2022 HF
- Source
- Taylor AL, et al. N Engl J Med. 2004;351(20):2049-2057.doi 10.1056/NEJMoa042934
Discussion & critique
Enrolled only self-identified Black patients already on ACEi/beta-blockers, limiting generalisability and raising questions about race-based prescribing. Established fixed-dose isosorbide dinitrate/hydralazine as add-on therapy.